MATTHEW GLENN: Open Payments
NPI 1225080419 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,892 in 114 payments from 22 companies in 2025. Trend: 2023 $2,504 · 2024 $2,103 · 2025 $1,892
Food & beverage: $1,892
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $362 |
| ABBVIE INC. | 21 | $330 |
| PFIZER INC. | 14 | $219 |
| AstraZeneca Pharmaceuticals LP | 4 | $161 |
| Amgen Inc. | 16 | $157 |
| Otsuka America Pharmaceutical, Inc. | 13 | $152 |
| Axsome Therapeutics, Inc. | 6 | $91 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $71 |
| Antares Pharma, Inc. | 3 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
Products named: Wegovy, VRAYLAR, REXULTI, OTEZLA, NURTEC ODT, FARXIGA, QULIPTA, XIFAXAN.
Industry payments across NE — which companies pay providers there.
